All In Biotech

Drug Trial Radar · NCT06984627

A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Actual

Start

Sep 2, 2025

Primary completion

Feb 11, 2027

Study completion Mar 11, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older. Study details include: * Screening period (up to 4 weeks). * Treatment period (up to 16 weeks). * Follow-up period (4 weeks). The number of visits will be up to 13.

Conditions

  • Graves' Disease

Interventions

  • Rilzabrutinib dose 1Drug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • Rilzabrutinib dose 2Drug

    Pharmaceutical form:Tablet-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in FT4 levelsTime frame: At Week16

Locations

24 sites in 9 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Córdoba, Argentina

  • Investigational Site Number : 1240003

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240002

    Surrey, British Columbia, Canada

  • Investigational Site Number : 1240001

    Sherbrooke, Quebec, Canada

  • Investigational Site Number : 1520001

    Concepción, Biobio, Chile

  • Investigational Site Number : 1520002

    Iquique, Tarapacá, Chile

  • Investigational Site Number : 2760002

    Essen, Germany

  • Investigational Site Number : 2760001

    Frankfurt, Germany

  • Investigational Site Number : 3000002

    Athens, Greece

  • Investigational Site Number : 3000001

    Athens, Greece

  • Investigational Site Number : 3000003

    Larissa, Greece

  • Investigational Site Number : 3480001

    Pécs, Hungary

  • Investigational Site Number : 3800005

    Merano, Italy

  • Investigational Site Number : 3800003

    Palermo, Italy

  • Investigational Site Number : 3800002

    Pisa, Italy

  • Investigational Site Number : 3800001

    Milan, Milano, Italy

  • Investigational Site Number : 3800004

    Milan, Milano, Italy

  • Investigational Site Number : 7240002

    Barcelona, Catalunya [Cataluña], Spain

  • Investigational Site Number : 7240001

    Pamplona, Navarre, Spain

  • Investigational Site Number : 7240004

    Seville, Sevilla, Spain

  • Investigational Site Number : 8260003

    Milton Keynes, Buckinghamshire, United Kingdom

  • Investigational Site Number : 8260001

    Newcastle upon Tyne, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.